Literature DB >> 17952119

A potential dichotomous role of ATF3, an adaptive-response gene, in cancer development.

X Yin1, J W Dewille, T Hai.   

Abstract

Activating transcription factor 3 (ATF3) is a member of the ATF/cyclic AMP response element-binding family of transcription factors. We present evidence that ATF3 has a dichotomous role in cancer development. By both gain- and loss-of-function approaches, we found that ATF3 enhances apoptosis in the untransformed MCF10A mammary epithelial cells, but protects the aggressive MCF10CA1a cells and enhances its cell motility. Array analyses indicated that ATF3 upregulates the expression of several genes in the tumor necrosis factor pathway in the MCF10A cells but upregulates the expression of several genes implicated in tumor metastasis, including TWIST1, fibronectin (FN)-1, plasminogen activator inhibitor-1, urokinase-type plasminogen activator, caveolin-1 and Slug, in the MCF10CA1a cells. We present evidence that ATF3 binds to the endogenous promoters and regulates the transcription of the TWIST1, FN-1, Snail and Slug genes. Furthermore, conditioned medium experiments indicated that ATF3 has a paracrine/autocrine effect, consistent with its upregulation of genes encoding secreted factors. Finally, ATF3 gene copy number is >2 in approximately 80% of the breast tumors examined (N=48) and its protein level is elevated in approximately 50% of the tumors. These results provided a correlative argument that it is advantageous for the malignant cancer cells to express ATF3, consistent with its oncogenic roles suggested by the MCF10CA1a cell data.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17952119     DOI: 10.1038/sj.onc.1210861

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  104 in total

1.  The stress response mediator ATF3 represses androgen signaling by binding the androgen receptor.

Authors:  Hongbo Wang; Ming Jiang; Hongmei Cui; Mengqian Chen; Ralph Buttyan; Simon W Hayward; Tsonwin Hai; Zhengxin Wang; Chunhong Yan
Journal:  Mol Cell Biol       Date:  2012-06-04       Impact factor: 4.272

2.  Convergent mutations and kinase fusions lead to oncogenic STAT3 activation in anaplastic large cell lymphoma.

Authors:  Ramona Crescenzo; Francesco Abate; Elena Lasorsa; Fabrizio Tabbo'; Marcello Gaudiano; Nicoletta Chiesa; Filomena Di Giacomo; Elisa Spaccarotella; Luigi Barbarossa; Elisabetta Ercole; Maria Todaro; Michela Boi; Andrea Acquaviva; Elisa Ficarra; Domenico Novero; Andrea Rinaldi; Thomas Tousseyn; Andreas Rosenwald; Lukas Kenner; Lorenzo Cerroni; Alexander Tzankov; Maurilio Ponzoni; Marco Paulli; Dennis Weisenburger; Wing C Chan; Javeed Iqbal; Miguel A Piris; Alberto Zamo'; Carmela Ciardullo; Davide Rossi; Gianluca Gaidano; Stefano Pileri; Enrico Tiacci; Brunangelo Falini; Leonard D Shultz; Laurence Mevellec; Jorge E Vialard; Roberto Piva; Francesco Bertoni; Raul Rabadan; Giorgio Inghirami
Journal:  Cancer Cell       Date:  2015-04-13       Impact factor: 31.743

3.  Activating transcription factor 3 promotes colon cancer metastasis.

Authors:  Zhi-Yong Wu; Zheng-Mao Wei; Sheng-Jie Sun; Jing Yuan; Shun-Chang Jiao
Journal:  Tumour Biol       Date:  2014-05-24

4.  The role of RhoC in the proliferation and apoptosis of hepatocellular carcinoma cells.

Authors:  Shuli Xie; Mingguang Zhu; Guoyue Lv; Qiang Zhang; Guangyi Wang
Journal:  Med Oncol       Date:  2011-06-15       Impact factor: 3.064

5.  Deficiency of Atf3, an adaptive-response gene, protects islets and ameliorates inflammation in a syngeneic mouse transplantation model.

Authors:  E J Zmuda; M Viapiano; S T Grey; G Hadley; A Garcia-Ocaña; T Hai
Journal:  Diabetologia       Date:  2010-03-28       Impact factor: 10.122

6.  Activating Transcription Factor 3 regulates in part the enhanced tumour cell cytotoxicity of the histone deacetylase inhibitor M344 and cisplatin in combination.

Authors:  Carly St Germain; Anna O'Brien; Jim Dimitroulakos
Journal:  Cancer Cell Int       Date:  2010-09-09       Impact factor: 5.722

7.  The ubiquitously expressed bZIP inhibitor, JDP2, suppresses the transcription of its homologue immediate early gene counterpart, ATF3.

Authors:  Keren Weidenfeld-Baranboim; Tal Hasin; Ilona Darlyuk; Ronit Heinrich; Ofer Elhanani; Jianzhi Pan; Kazunari K Yokoyama; Ami Aronheim
Journal:  Nucleic Acids Res       Date:  2009-02-20       Impact factor: 16.971

8.  A resampling-based meta-analysis for detection of differential gene expression in breast cancer.

Authors:  Bala Gur-Dedeoglu; Ozlen Konu; Serkan Kir; Ahmet Rasit Ozturk; Betul Bozkurt; Gulusan Ergul; Isik G Yulug
Journal:  BMC Cancer       Date:  2008-12-30       Impact factor: 4.430

9.  Circulating tumour cells demonstrate an altered response to hypoxia and an aggressive phenotype.

Authors:  K Ameri; R Luong; H Zhang; A A Powell; K D Montgomery; I Espinosa; D M Bouley; A L Harris; S S Jeffrey
Journal:  Br J Cancer       Date:  2010-01-05       Impact factor: 7.640

10.  Expression of stress-response ATF3 is mediated by Nrf2 in astrocytes.

Authors:  Kyu-Han Kim; Jae-Yeon Jeong; Young-Joon Surh; Kyu-Won Kim
Journal:  Nucleic Acids Res       Date:  2009-10-28       Impact factor: 16.971

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.